Description

Formulations:

• Dexlansoprazole Capsules: Available in strengths of 30mg and 60mg, our capsules provide sustained acid suppression to effectively manage acid-related disorders.

Indications:

• Dexlansoprazole is indicated for the treatment of:
  • Gastroesophageal reflux disease (GERD), including erosive esophagitis
  • Healing and maintenance of healing of erosive esophagitis
  • Symptomatic relief of heartburn associated with GERD

Pharmacokinetics:

• Absorption: Dexlansoprazole is rapidly absorbed after oral administration, with peak plasma concentrations achieved within 2-4 hours.
• Distribution: It is extensively distributed throughout the body, with high concentrations found in the gastric parietal cells.
• Metabolism: Dexlansoprazole undergoes hepatic metabolism primarily by the cytochrome P450 enzyme system, with the main metabolites being inactive.
• Elimination: The elimination half-life of dexlansoprazole is approximately 1-2 hours, with the majority of the drug excreted in the urine.

Pharmacodynamics:

• Dexlansoprazole selectively inhibits the proton pump in the gastric parietal cells, leading to profound and sustained suppression of gastric acid secretion. This mechanism of action provides rapid symptom relief and promotes healing of mucosal damage associated with acid-related disorders.

Usage:

• Dexlansoprazole capsules should be swallowed whole with water, preferably before meals.
• The capsules should not be crushed or chewed, as this may affect drug absorption and efficacy.

Dosage:

• The recommended dosage of dexlansoprazole varies depending on the indication and severity of the condition. It is typically administered once daily.

Side Effects:

• Common side effects of dexlansoprazole may include:
  • Headache
  • Nausea
  • Diarrhea
  • Abdominal pain
• Serious side effects such as Clostridium difficile-associated diarrhea and hypomagnesemia may occur but are rare.

Experience the efficacy and reliability of AIT Pharmaceuticals Division’s Dexlansoprazole Range in the management of acid-related disorders. For more information, please contact us.